» Articles » PMID: 31719636

Insulin Enhancement of the Antitumor Activity of Chemotherapeutic Agents in Colorectal Cancer is Linked with Downregulating PIK3CA and GRB2

Overview
Journal Sci Rep
Specialty Science
Date 2019 Nov 14
PMID 31719636
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The present state of cancer chemotherapy is unsatisfactory. New anticancer drugs that marginally improve the survival of patients continue to be developed at an unsustainably high cost. The study aimed to elucidate the effects of insulin (INS), an inexpensive drug with a convincing safety profile, on the susceptibility of colon cancer to chemotherapeutic agents: 5-fluorouracil (FU), oxaliplatin (OXA), irinotecan (IRI), cyclophosphamide (CPA) and docetaxel (DOC). To examine the effects of insulin on cell viability and apoptosis, we performed an in vitro analysis on colon cancer cell lines Caco-2 and SW480. To verify the results, we performed in vivo analysis on mice bearing MC38 colon tumors. To assess the underlying mechanism of the therapy, we examined the mRNA expression of pathways related to the signaling downstream of insulin receptors (INSR). Moreover, we performed Western blotting to confirm expression patterns derived from the genetic analysis. For the quantification of circulating tumor cells in the peripheral blood, we used the maintrac method. The results of our study show that insulin-pretreated colon cancer cells are significantly more susceptible to commonly used chemotherapeutics. The apoptosis ratio was also enhanced when INS was administered complementary to the examined drugs. The in vivo study showed that the combination of INS and FU resulted in significant inhibition of tumor growth and reduction of the number of circulating tumor cells. This combination caused a significant downregulation of the key signaling substrates downstream of INSR. The results indicate that the downregulation of PIK3CA (phosphatidylinositol 3-kinase catalytic subunit alpha), which plays a critical role in cell signaling and GRB2 (growth factor receptor-bound protein 2), a regulator of cell proliferation and differentiation may be responsible for the sensitizing effect of INS. These findings were confirmed at protein levels by Western blotting. In conclusion, these results suggest that INS might be potentially applied to clinical use to enhance the therapeutic effectiveness of chemotherapeutic drugs. The findings may become a platform for the future development of new and inexpensive strategies for the clinical chemotherapy of tumors.

Citing Articles

Preclinical-to-clinical Anti-cancer Drug Response Prediction and Biomarker Identification Using TINDL.

Hostallero D, Wei L, Wang L, Cairns J, Emad A Genomics Proteomics Bioinformatics. 2023; 21(3):535-550.

PMID: 36775056 PMC: 10787192. DOI: 10.1016/j.gpb.2023.01.006.


Identification of a novel lipid metabolism-related gene signature for predicting colorectal cancer survival.

Huang Y, Zhou J, Zhong H, Xie N, Zhang F, Zhang Z Front Genet. 2022; 13:989327.

PMID: 36147494 PMC: 9485806. DOI: 10.3389/fgene.2022.989327.


Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer.

Harvie M, Pegington M, Howell S, Bundred N, Foden P, Adams J Br J Cancer. 2021; 126(8):1157-1167.

PMID: 34912072 PMC: 9023522. DOI: 10.1038/s41416-021-01650-0.


Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents.

Vekic J, Zeljkovic A, Stefanovic A, Giglio R, Ciaccio M, Rizzo M Int J Mol Sci. 2021; 22(22).

PMID: 34830295 PMC: 8622770. DOI: 10.3390/ijms222212409.


KPNA2-Associated Immune Analyses Highlight the Dysregulation and Prognostic Effects of GRB2, NRAS, and Their RNA-Binding Proteins in Hepatocellular Carcinoma.

Zhang X, Zhang J, Gao F, Fan S, Dai L, Zhang J Front Genet. 2020; 11:593273.

PMID: 33193737 PMC: 7649362. DOI: 10.3389/fgene.2020.593273.

References
1.
Shackney S, McCormack G, Cuchural Jr G . Growth rate patterns of solid tumors and their relation to responsiveness to therapy: an analytical review. Ann Intern Med. 1978; 89(1):107-21. DOI: 10.7326/0003-4819-89-1-107. View

2.
Hu T, Li Z, Gao C, Cho C . Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World J Gastroenterol. 2016; 22(30):6876-89. PMC: 4974586. DOI: 10.3748/wjg.v22.i30.6876. View

3.
Pollak M . Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008; 8(12):915-28. DOI: 10.1038/nrc2536. View

4.
Sachdev D, Yee D . Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther. 2007; 6(1):1-12. DOI: 10.1158/1535-7163.MCT-06-0080. View

5.
Hammond W, Swaika A, Mody K . Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016; 8(1):57-84. PMC: 4699262. DOI: 10.1177/1758834015614530. View